Key facts
- Primaa’s last known valuation is $73.9M (Oct 2025).
- It has raised $18.0M; the latest was Later Stage VC ($8.2M) in Oct 2025.
- Notable investors include Bpifrance, Agoranov, Super Capital, Elaia Partners, 50 Partners — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Primaa
- ·The full record, as it builds
Funding rounds
No funding rounds for Primaa are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Primaa
Developer of a medical diagnostic software designed for automated and accurate histological diagnoses. The company's software is an artificial intelligence-based tool that facilitates cancer detection by digitizing the slides and collecting images in a database, enabling clients to digitally identify tissue damage and perform an increasing number of diagnoses while maintaining an unwavering level of reliability.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2018
- Employees
- 25
- Website
- primaalab.com/
- Ownership
- Privately Held (backing)
Primaa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Primaa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Primaa in its N-PORT filings yet. We sweep new filings monthly.